Significant biosimilar activities this week include
11 May 20 | AstraZeneca announced it had recovered the global rights to brazikumab from Amgen. AstraZeneca had previously collaborated with Amgen to jointly develop and commercialise the product. Brazikumab is a monoclonal antibody targeting IL-23 and is currently in Ph II and Ph III trials for the treatment of ulcerative colitis and Crohn’s disease. The American Journal of Managed Care reported the development, noting the role the AbbVie-Allergan merger and the FTC played in facilitating the deal. The FTC ruled that as both AbbVie and Allergen were developing IL-23 inhibitors, there would not be a sufficiently competitive environment for these products unless brazikumab was released from Amgen/Allergan.
18 May 20 | Samsung Bioepis announced 24-week interim results from a Ph III trial of SB11 (a proposed ranibizumab biosimilar) in patients with neovascular age-related macular degeneration. Samsung Bioepis announced that the primary endpoints of the trial were met, suggesting that SB11 will be a valuable treatment option for nAMD.
18 May 20 | JHL Biotech announced that the first group of subjects in the Australian randomised Ph I trials of JHL1266 (proposed denosumab) were dosed.
19 May 20 | Korea Biomedical Review announced that Daewon Pharmaceutical has launched Terrosa® (teriparatide) in South Korea. Terrosa® was developed by Gedeon Richter and is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture, and osteoporosis associated with sustained systemic glucocorticoid therapy in men and women at increased risk for fracture.
22 May 20 | JD Supra reported on Mylan’s Q1 earnings call. In the call, Mylan announced its partner Biocon had received FDA pre-approval of its Malaysian manufacturing facility, as well as announcing a planned launch for Nepexto® (etanercept) in Europe within months. The BLA and marketing authorisation for its bevacizumab candidate is currently under review by the FDA and European authorities. Mylan also confirmed that its biosimilar insulin and aflibercept projects remain on target.
22 May 20 | Fresenius Kabi announced that the EMA has accepted its marketing application for MSB11455, a proposed pegfilgrastim biosimilar.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.